ArticleFrontiers in neurology
Impact of cerebral small vessel disease burden and systemic clinical phenotypes on short-term neurological outcomes after acute ischemic stroke.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebral small vessel disease (CSVD) is increasingly recognized as an important determinant of outcome after acute ischemic stroke (AIS). However, the contribution of global CSVD burden, individual imaging markers, and systemic clinical phenotypes to early neurological recovery remains incompletely understood. Methods: We conducted a retrospective cohort study of consecutive AIS patients admitted to Dongzhimen Hospital, Beijing University of Chinese Medicine between January and December 2024. CSVD markers were assessed using MRI according to STRIVE criteria, and a total CSVD burden score (0-4) was calculated. Systemic clinical phenotypes were defined based on standardized admission assessments. The primary outcome was unfavorable neurological status at discharge (NIHSS >8). Multivariable logistic regression with collinearity diagnostics was performed. Distributions of NIHSS scores across CSVD features were visualized using violin plots. Results: A total of 474 patients were included (median age 67 years; 71% male), of whom 31 (6.5%) had unfavorable outcomes. Higher total CSVD burden (adjusted OR 1.57, 95% CI 1.13-2.17), hyperhomocysteinemia (adjusted OR 2.76, 95% CI 1.21-6.31), and a Traditional Chinese Medicine (TCM)-defined Phlegm-Heat Fu-Excess phenotype (adjusted OR 5.28, 95% CI 1.85-15.04) were independently associated with unfavorable outcomes. Among individual CSVD markers, lacunar infarction showed the strongest association. White matter hyperintensities, cerebral atrophy, and basal ganglia enlarged perivascular spaces were associated with higher discharge NIHSS scores in exploratory analyses. Given the limited number of outcome events, the stability of the regression model may be limited, and these findings should be interpreted with caution. Discussion: Global CSVD burden and selected systemic clinical phenotypes are associated with poor short-term neurological outcomes after AIS. These findings should be considered exploratory and hypothesis-generating, and may provide supplementary information for early risk stratification. Further validation in larger, prospective multicenter studies is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.